UNASSIGNED:国际指南推荐细针穿刺细胞学检查(FNAC)用于术前评估>1cm的可疑甲状腺结节。尽管来自内分泌中心的有力证据表明FNAC结果对手术指征的关键作用,该方法在欧洲诊所中不常用.数据库EUROCRINE®,这是在2015年引入的,涉及内分泌系统的注册操作范围,允许对欧洲有关FNAC使用和相关准确性的当前服务现实进行大规模分析。
未经评估:为“排除恶性肿瘤”而进行的操作,2015年1月至2018年12月在EUROCRINE®注册,进行了分析。计算FNAC的精度参数。在BethesdaIV类的情况下,FNAC结果被认为是“测试阳性”,V,VI,因为这些类别通常会提示欧洲甲状腺手术中心的手术干预。贝塞斯达II类和III类被认为是“测试阴性”。
未经批准:在8,791个操作中,5,780例术前FNAC(65.7%)。总体恶性率为28.3%(2,488/8,791)。贝塞斯达六世的恶性肿瘤率为68.8%,贝塞斯达五世的69.9%,贝塞斯达四世的32.6%,III的28.2%,贝塞斯达二世为20.2%,贝塞斯达I为24.5%。排除乳头状微癌(PTMCs)后,FNAC的敏感性为71.7%,特异性为43.5%,阳性预测值为29.1%,阴性预测值为82.7%。
未经证实:尽管“排除恶性肿瘤”的指征是本队列中促使甲状腺切除术的主要原因,FNAC仅在约65.7%的病例中使用。执行时,FNAC与出乎意料的低准确度相关。有趣的是,在贝塞斯达二世,存在20.2%的恶性实体(排除PTMC后为13.3%)。
UNASSIGNED: Fine-needle aspiration cytology (FNAC) is recommended by international guidelines for the preoperative evaluation of suspicious thyroid nodules >1 cm. Despite robust evidence from endocrine centers demonstrating the key role of FNAC results for the indication of surgery, the method is not routinely used in European clinics. The database EUROCRINE®, which was introduced in 2015 with the scope of registering operations of the endocrine system, allows for a large-scale analysis of the current service reality in Europe concerning FNAC use and associated accuracy.
UNASSIGNED: Operations performed to \"exclude malignancy\", registered from January 2015 to December 2018 in EUROCRINE®, were analyzed. Parameters of accuracy were calculated for FNAC. FNAC results were considered \"test positive\" in the case of Bethesda category IV, V, and VI, since these categories usually prompt surgical interventions in European centers for thyroid surgery. Bethesda category II and III were considered \"test negative\".
UNASSIGNED: Of 8,791 operations, 5,780 had preoperative FNAC (65.7%). The overall malignancy rate was 28.3% (2,488/8,791). Malignancy rates were 68.8% for Bethesda VI, 69.9% for Bethesda V, 32.6% for Bethesda IV, 28.2% for III, 20.2% for Bethesda II, and 24.5% for Bethesda I. After exclusion of papillary microcarcinomas (PTMCs), the sensitivity of FNAC was 71.7% and specificity 43.5%, the positive predictive value was 29.1% and the negative predictive value 82.7%.
UNASSIGNED: Although the indication to \"exclude malignancy\" was the predominant reason that prompted thyroid resection in the present cohort, FNAC was only used in about 65.7% of cases. When performed, FNAC was associated with unexpectedly low accuracy. Interestingly, in Bethesda II, 20.2% of malignant entities were present (13.3% after the exclusion of PTMCs).